Does exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) attenuate the glycaemic response to small intestinal nutrient in critically ill patients?
The effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) on glycaemia in critically ill patients
Adam Deane
20 participants
Aug 25, 2011
Interventional
Conditions
Summary
The primary objective of this study is to establish if exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 (both hormones released from the gastrointestinal tract) has a glucose lowering effect in critically ill patients
Eligibility
Inclusion Criteria3
- Mechanically ventilated critically ill patients.
- Suitable for, or receiving post-pyloric nutrition.
- Likely to stay ventilated for at least 48 hours.
Exclusion Criteria5
- A history of diabetes.
- Pregnancy.
- Contraindication to placement of a post-pyloric feeding tube or enteral feeding.
- Previous surgery on the small intestine.
- Any gastrointestinal surgery during their current hospital admission.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Study Drug: Glucose-dependent insulinotropic polypeptide (GIP)at 2pmol.kg.min & glucagon-like peptide-1 (GLP-1) at 1.2pmol.kg.min Infused intravenously from 0-270mins or Control: 0.9% saline & GLP-1 at 1.2pmol/kg/min Infused intravenously from 0-270mins Patients will be studied on consecutive days (i.e. 24 hour washout period)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000735954